Legend Biotech requests that their press release NewsItemId: 20211206005107 “Legend Biotech Announces Submission of New Drug Application to Japanese Regulatory Authority for BCMA CAR-T Therapy Cilta-cel for the Treatment of Relapsed or Refractory Multiple Myeloma by Janssen” be killed.
The release was issued prematurely by Legend Biotech. The release will be reissued at a later date.
Crystal Chen, Manager of Investor Relations and Corporate Communications, Legend Biotech email@example.com
Tina Carter, Corporate Communications Lead, Legend Biotech